Ideal antiplatelet therapy for coronary artery disease: focus on adenosine diphosphate receptor inhibitors.
about
Cardiac purinergic signalling in health and diseaseAdvances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelorEmerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.Novel anti-platelet agents in acute coronary syndrome: mechanisms of action and opportunities to tailor therapy.
P2860
Ideal antiplatelet therapy for coronary artery disease: focus on adenosine diphosphate receptor inhibitors.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Ideal antiplatelet therapy for ...... phosphate receptor inhibitors.
@ast
Ideal antiplatelet therapy for ...... phosphate receptor inhibitors.
@en
type
label
Ideal antiplatelet therapy for ...... phosphate receptor inhibitors.
@ast
Ideal antiplatelet therapy for ...... phosphate receptor inhibitors.
@en
prefLabel
Ideal antiplatelet therapy for ...... phosphate receptor inhibitors.
@ast
Ideal antiplatelet therapy for ...... phosphate receptor inhibitors.
@en
P2093
P1476
Ideal antiplatelet therapy for ...... phosphate receptor inhibitors.
@en
P2093
Parinda Shah
Rohit Arora
Rohit Loomba
Suraj Chandrasekar
P304
P356
10.1097/MJT.0B013E31820B8668
P577
2013-07-01T00:00:00Z